Peter Kourlas is an Oncology physician affiliated with Columbus Oncology and Hematology Associates. OpenAlex indexes 13 publications with 758 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
810 Jasonway Ave Ste A
Columbus, OH 432144359
Telephone
614-442-3130Provider last certified this registry record 12 Aug 2024.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- OCCLUTECH US LLCProgram year20241 payment
- Genentech USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
50.4%Parenteral Iron Replacement28%Iron sucrose100%Part B, office-administered≥12 patientsErythropoiesis-stimulating Agent22.1%Darbepoetin alfa100%Part B, office-administered≥12 patients+ 1 more class in this area
Metabolism & gastrointestinal
25.1%Other antiemetics20.5%Fosaprepitant100%Part B, office-administered≥21 patientsSerotonin-3 Receptor Antagonist4.4%Ondansetron hydrochloride59%Palonosetron hcl37%Ondansetron Hcl4%Ondansetron Odt1%Part D + Part B<11 patients+ 3 more classes in this area
Cancer & immunology
20%PD-1 inhibitor18.9%Pembrolizumab100%Part B, office-administered≥13 patientsKinase inhibitor0.4%Calquence22%Imatinib Mesylate22%Ibrance18%Brukinsa16%Imbruvica13%Cabometyx9%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
JNCI Journal of the National Cancer Institute
2021 - Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.
Journal of Clinical Oncology
2020 - Macrophage Activation Syndrome (MAS) in a Recently Released Prisoner with Systemic Lupus Erythematosus (SLE)
American Journal of Case Reports
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Erin Macrae, MD
Columbus Oncology and Hematology Associates
Elena Christofides, MD, FACE
Columbus Oncology and Hematology Associates
Jarred Burkart, MD
Columbus Oncology and Hematology Associates
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”